Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods

Journal of Clinical Psychiatry

Volumn 67, Issue 10, 2006, Pages 1493-1500

  Van Winkel, Ruud ^a   De Hert, Marc ^a,c   Van Eyck, Dominique ^a   Hanssens, Linda ^b   Wampers, Martien ^a   Scheen, Andre ^b   Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; GOLD STANDARD; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METABOLIC DISORDER; MORBIDITY; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCREENING TEST; SENSITIVITY ANALYSIS; WORLD HEALTH ORGANIZATION;

EID: 33747107933     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n1002     Document Type: Article

References (55)

1. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60(suppl 21):10-15
2. Jones DR, Macias C, Barreira PJ, et al. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatr Serv 2004;55:1250-1257
3. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust 2003:178:S67-S70
4. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
5. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66:1116-1121
6. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002;63:1135-1139
7. Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 2003;37:1849-1857
8. Gianfrancesco F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003;23:328-335
9. Hedenmalm K, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107-1116
10. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16:77-89
11. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296
12. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004;64:701-723
13. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
14. Carlson C, Hornbuckle K, Delisle F, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol 2006;16:366-375
15. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003;26:1597-1605
16. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005;66:504-514
17. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
18. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-289
19. De Hert M, Van Eyck D, Hanssens L, et al. Oral glucose tolerance tests in treated patients with schizophrenia: data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 2006;21:224-226
20. Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6:314-318
21. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760
22. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579
23. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
24. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93
25. American Diabetes Association, American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
26. Adam JM, Tarigan NP. Comparison of the World Health Organization (WHO) two-step strategy and OGTT for diabetes mellitus screening. Acta Med Indones 2004;36:3-7
27. Botas P, Delgado E, Castano G, et al. Comparison of the diagnostic criteria for diabetes mellitus, WHO-1985. ADA-1997 and WHO-1999 in the adult population of Asturias (Spain). Diabet Med 2003;20:904-908
28. Ananth J, Venkatesh R, Burgoyne K, et al. Atypical antipsychotic drug use and diabetes. Psychother Psychosom 2002;71:244-254
29. Rigalleau V, Gatta B, Bonnaud S, et al. Diabetes as a result of atypical anti-psychotic drugs: a report of three cases. Diabet Med 2000;17:484-486
30. Peuskens H, De Hert M, Van Eyck D, et al. A case of reversible olanzapine-induced diabetes after switching to risperidone. Adv Schiz Clin Psych 2004;1:31-33
31. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull [Epub ahead of print] Aug 29, 2006
32. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Report of a WHO Consultation, pt 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: Department of Noncommunicable Disease Surveillance; 1999
33. Hilton DJ, O'Rourke PK, Welborn TA, et al. Diabetes detection in Australian general practice: a comparison of diagnostic criteria. Med J Aust 2002;176:104-107
34. Tai ES, Lim SC, Tan BY, et al. Screening for diabetes mellitus: a two-step approach in individuals with impaired fasting glucose improves detection of those at risk of complications. Diabet Med 2000;17:771-775
35. Cheng C, Kushner H, Falkner BE. The utility of fasting glucose for detection of prediabetes. Metabolism 2006;55:434-438
36. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5-S20
37. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
38. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-2752
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:32
40. Walckiers D, Van der Veken J, Papoz L, et al. Prevalence of drug-treated diabetes mellitus in Belgium: results of a study with the collaboration of a network of pharmacies. Eur J Clin Pharmacol 1992;43:613-619
41. Hortulanus-Beck D, Lefebvre PJ, Jeanjean MF. Diabetes in the Belgian province of Luxembourg: frequency, importance of the oral glucose tolerance test and a modestly increased fasting blood glucose. Diabetes Metab 1990;16:311-317
42. Wampers M, De Hert M, Van Eyck D, et al. Somatic medication in hospitalised schizophrenic patients in Belgium [abstracts from the Winter Workshop on Schizophrenia]. Schizophr Res 2004;67:152-153
43. Hanssens L, De Hert M, Wampers M, et al. Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemiol Ment Health 2006;2:11
44. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161:1709-1711
45. Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193:387-395
46. Lambert M, Copeland L, Sampson N, et al. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:919-923
47. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405
48. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio Heart Study. Diabetes Care 2003;26:3153-3159
49. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-581
50. CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998;280:1757-1768
51. Gianfrancesco F, Pesa J, Wang RH, et al. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am J Health Syst Pharm 2006;63:431-441
52. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508
53. Joukamaa M, Heliovaara M, Knekt P, et al. Mental disorders and cause-specific mortality. Br J Psychiatry 2001;179:498-502
54. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28
55. Ford ES, Mokdad AH, Giles WH, et al. Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors. Obes Res 2005;13:118-122